Department of Throracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
FEBS Lett. 2013 Nov 15;587(22):3661-7. doi: 10.1016/j.febslet.2013.09.018. Epub 2013 Sep 23.
Non-small cell lung cancer (NSCLC) is one of the most common causes for lung cancer and cancer-related death. The imbalance between cell proliferation and apoptosis was suggested to play an important role in cancer pathogenesis and PKCε is one of the widely recognized targets. Here, we demonstrate that miR-143 is aberrantly downregulated in NSCLC tissue and negatively correlates with expression of PKCε. We show that miR-143 specifically targets the 3'-UTR of PKCε and regulates its expression. Treatment with miR-143 inhibitor mimics cell proliferation and apoptosis imbalance in NSCLC, while inhibition of PKCε can reverse it. Our findings suggest that targeting PKCε overexpression in NSCLC should be beneficial for lung cancer therapy.
非小细胞肺癌（NSCLC）是肺癌和癌症相关死亡的最常见原因之一。细胞增殖和凋亡失衡被认为在癌症发病机制中起重要作用，PKCε 是广泛认可的靶点之一。在这里，我们证明 miR-143 在 NSCLC 组织中异常下调，并与 PKCε 的表达呈负相关。我们表明 miR-143 特异性靶向 PKCε 的 3'-UTR 并调节其表达。用 miR-143 抑制剂处理可模拟 NSCLC 中的细胞增殖和凋亡失衡，而抑制 PKCε 可以逆转这种失衡。我们的研究结果表明，针对 NSCLC 中的 PKCε 过表达进行靶向治疗可能有益于肺癌治疗。
